Evaluation of a Bayesian hierarchical pharmacokinetic-pharmacodynamic model for predicting parasitological outcomes in Phase 2 studies of new antimalarial drugs

Meg K Tully¹, Saber Dini¹, Jennifer A Flegg², James S McCarthy^{3,4,5}, David J Price^{1,3,†}, Julie A Simpson^{1,6†,*}

¹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia

²School of Mathematics and Statistics, The University of Melbourne, Melbourne, Australia ³Department of Infectious Diseases, The University of Melbourne, at the Peter Doherty Institute for Infection & Immunity, Melbourne, Australia

⁴Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, Australia

⁵Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia ⁶Nuffield Department of Medicine, University of Oxford, Oxford, UK

 † Co-senior authors

* Corresponding author: julieas@unimelb.edu.au

Key words: pharmacokinetic-pharmacodynamic modelling, antimalarial, Bayesian methods, simulation

CONFLICT OF INTEREST

All authors declared no competing interests for this work.

FUNDING

This work was supported by the Australian National Health and Medical Research Council (NHMRC) Leadership Investigator Grants (#1196068) to JAS and and (#2016396) to JSM, the Australian Centre for Research Excellence in Malaria Elimination (#2024622) and a NHMRC Synergy Grant (#2018654).

1 Abstract

The rise of multidrug resistant malaria requires accelerated development of novel antimalarial drugs. Pharmacokinetic-pharmacodynamic (PK-PD) models relate blood antimalarial drug concentrations with the parasite-time profile to inform dosing regiments. We performed a simulation study to assess the utility of a Bayesian hierarchical mechanistic PK-PD model for predicting parasite-time profiles for a Phase 2 study of a new antimalarial drug, cipargamin.

⁸ We simulated cipargamin concentration- and malaria parasite-profiles based on a ⁹ Phase 2 study of 8 volunteers who received cipargamin 7 days after inoculation with ¹⁰ malaria parasites. The cipargamin profiles were generated from a 2-compartment ¹¹ PK model and parasite profiles from a previously published biologically informed PD ¹² model. One-thousand PK-PD datasets of 8 patients were simulated, following the ¹³ sampling intervals of the Phase 2 study. The mechanistic PK-PD model was incor-¹⁴ porated in a Bayesian hierarchical framework and the parameters estimated.

Population PK model parameters describing absorption, distribution and clearance were estimated with minimal bias (mean relative bias ranged from 1.7 to 8.4%). The PD model was fitted to the parasitaemia profiles in each simulated dataset using the estimated PK parameters. Posterior predictive checks demonstrate that our PK-PD model successfully captures both the pre- and post-treatment simulated PD profiles. The bias of the estimated population average PD parameters was low-moderate in magnitude.

This simulation study demonstrates the viability of our PK-PD model to predict parasitological outcomes in Phase 2 volunteer infection studies. This work will inform the dose-effect relationship of cipargamin, guiding decisions on dosing regimens to evaluate in Phase 3 trials.

²⁶ 1 Introduction

Almost 40% of the global population live in malaria endemic areas, with an estimated 249 million clinical cases in 2022, and over 608,000 deaths [1]. Following a significant fall in the global malaria burden between 2005 and 2015, the estimated number of malaria cases and deaths has begun to rise over recent years [1]. The availability of effective antimalarial drugs is key to reducing the burden of morbidity and mortality attributable to malaria.

Artemisinin-based combination therapies (ACTs), comprised of a highly potent 33 and rapid-acting artemisinin-derivative with a longer-acting partner drug, are the 34 current first-line treatment for *Plasmodium falciparum* malaria infection. However, 35 partial resistance to artemisining is now widespread across Southeast Asia [2] and 36 more recently, has emerged de novo in some African countries [3, 4], South America 37 [5] and Papua New Guinea [6]. Moreover, resistance to the partner drugs used in 38 ACTs, such as piperaquine, has also been detected in Southeast Asia [7], resulting in 39 treatment failures. New antimalarial drugs are urgently needed. 40

Drug development is a resource-heavy, expensive and time-consuming process, 41 with only approximately 10% of drugs tested in Phase 1 trials ultimately gaining 42 approval [8]. The journey from early phase clinical trials to Phase 3 clinical trials 43 in patients, to then drug registration, can take many years [9]. Cipargamin is a 44 promising candidate antimalarial drug that has transitioned from early phase studies 45 [10] to Phase 2 clinical trials of adult patients with falciparum malaria [11, 12]. In 46 particular, it is a rapidly acting parenteral agent with promise to replace artemisinin 47 [13]. McCarthy and colleagues investigated the efficacy of cipargamin in a Phase 2 48 clinical trial [14] in 8 healthy volunteer patients who were experimentally infected 49 with malaria and seven days later administered a low dose (10mg) of cipargamin. 50

These human challenge studies, also known as volunteer infection studies, involve 51 purposeful infection of healthy volunteers in a controlled environment, and produce 52 rich data on both parasite and drug concentrations through frequent sampling [15]. 53 Given the ethical considerations of infecting healthy volunteers, it is imperative that 54 the maximum information possible is obtained from these data, in order to guide 55 selection of dosing regimens investigated for future Phase 2 and 3 studies. Statistical 56 methods that are tailored to generating inferences from these valuable data are thus 57 required. Pharmacokinetic-Pharmacodynamic (PK-PD) modelling is a typical frame-58 work used for such analyses. These models integrate the PK model, that describes 59 the drug concentration over time, with a PD model that characterises the drug's ef-60 fect on the parasite population. Ideally, a PK-PD model should capture key elements 61 of the underlying biological system, whilst remaining sufficiently simple for practical 62 estimation and interpretation of key parameters [16]. 63

In this study we assessed an adaptation of an existing mechanistic Bayesian hierarchical PK-PD model developed by Dini *et al.* [17], which captures the life cycle of the parasite within the red blood cell. Within a simulation-estimation framework, we investigated how precisely and accurately this model was able to recover the PK and PD parameters. The simulation study is based on data from the Phase 2 clinical study of cipargamin [14].

$_{70}$ 2 Results

A detailed description of the PK model, PD model, the Bayesian inference framework, and simulation study setup, including all model parameters, are provided in
the Methods section. Definitions of the PK and PD model parameters are given in
Tables 1 and 2 with a study overview diagram provided in Figure 1.

75

76 Pharmacokinetic Model

Cipargamin concentrations were simulated using a 2-compartment PK model with 77 first-order absorption, based on the estimated PK parameters and between-individual 78 variability from the analysis of the Phase 2 trial PK data [14] (Table 3). A total 79 of 1000 simulated datasets were generated, each dataset included the PK and PD 80 profiles of 8 patients, incorporating between- and within-individual variability. The 81 simulated 8-patient PK datasets provided a good visual match to the trial data from 82 McCarthy et al. [14] (Figure S1). The PK model was incorporated into a Bayesian 83 hierarchical framework, and fitted to each of the 1000 simulated datasets, restricting 84 data to the cipargamin concentrations which correspond to the sampling times of 85 the original Phase 2 trial (1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours 86 post-treatment), and the posterior median estimate of each population PK parameter 87 obtained. To evaluate how accurately this model can estimate PK parameters, we 88 calculated the difference (absolute and relative bias) between the posterior median 89 estimate of the population-level PK parameter, and the value used to simulate the 90 data (*i.e.*, the 'true' value). Table 4 shows the 'true' PK parameter values used to 91 simulate the data, the mean, 2.5- and 97.5-percentiles (herein, 95% intervals) across 92 the 1000 posterior median estimates associated with each simulation, and the bias 93 (absolute and relative) in these posterior median estimates. The population-level 94

PK parameters were reliably estimated, with the magnitude of relative bias ranging from 1.7% to 8.4%, comparing the mean of the posterior median estimates to the 'true' value. To contextualise the bias in these estimates, we compared the PK profile created by the 'true' population parameters to the PK profiles generated at the 1000 posterior median parameter estimates (Figure 2). This figure demonstrates that the average PK profiles for cipargamin are captured well across all simulations.

The population-level PK parameter least accurately estimated by the model was 101 the absorption parameter, k_a , with a mean relative bias of 8.4% [95% intervals (-9.7%, 102 32%)]. The PK profiles exhibit a short and sharp rise in drug concentration upon 103 administration, during which absorption may be estimated, however the availability of 104 only 1 to 2 observations from this period impedes the estimation of the k_a parameter. 105 When the drug concentration profiles produced from the 'actual' and 'estimated' PK 106 parameters were compared (Figure 2), it is clear that the discrepancies between the 107 absorption parameter values do not materially impact the cipargamin concentrations 108 during the distribution and elimination phases. 109

To investigate how well this framework can recover model parameters for a single experiment, we show an example of the posterior samples compared to the 'true' value in Figure 3. These show that the true parameter values are contained within the range of posterior samples for each parameter, considering pairwise correlations. FigureS4 shows the posterior predictive pharmacokinetic profiles for each of the eight patients in a single experiment, again demonstrating that the posterior model fit provides an accurate characterisation of the pharmacokinetic profile.

117

¹¹⁸ Pharmacodynamic Model

For each of the above simulated 1000 datasets, the 8 individual cipargamin concentrationtime profiles were used to simulate 8 parasite count profiles. These parasitaemia pro-

files were simulated for the initial 7 days of parasite growth post-inoculation. The 121 simulated cipargamin concentration profiles were then used to simulate drug-induced 122 killing of the parasites over the next two days, post cipargamin administration on day 123 7. The PD model simulated the number of parasites aged 1 to 40 hours at each time 124 point, and data for fitting the model was again restricted to the sampling times of the 125 original study (72, 96, 108, 120, 132, 144, 156, 168, 172, 176, 180, 184, 192, 198, 204, 126 216, 228, 240, 264 and 288 hours post-innoculation). We assumed cipargamin had an 127 immediate effect on the parasite, and that the concentration-effect relationship fol-128 lowed Michaelis-Menten kinetics. The PD parameter values and between-individual 129 variability selected for generation of the PD profiles are provided in Table 5. The 130 1000 simulated PD datasets provided a good visual match to the parasitaemia data 131 from McCarthy *et al.* [14] (Figure S5). 132

Table 6 shows the 'true' PD parameter values, the mean and 95% intervals across 133 the 1000 posterior median estimates, and the absolute and relative bias in the poste-134 rior median estimates for each PD parameter. The magnitude of relative bias for the 135 posterior median estimates of the seven PD parameters varied between 1% and 53%. 136 As per the PK evaluation, we contextualised this bias by plotting a profile produced 137 by the mean PD parameter estimates for each of the 1000 simulations, and compared 138 these to the PD profile created by the parameters used to simulate the data (Figure 139 4). 140

The 'true' mean initial parasite age (μ_{ipl}) was 2 hours, but had a mean estimate of 2.96 hours (95% quantiles: [2.69, 3.44]). Although a seemingly large relative bias (48% [34.50%, 72.0%]), this discrepancy is less than one hour difference in parasite age. These still represent a mean age of parasites in the early ring stage of the parasite life cycle. Estimates of the standard deviation of the initial parasite age (σ_{ipl}) are associated with a similarly large relative bias (-53.3%, [-57.3%, -48.3%]). When we ¹⁴⁷ compared the profiles produced by the estimated and 'true' values, (Figure 4) the
¹⁴⁸ bias in these estimates had a negligible impact on the overall parasite dynamics.

The estimated values of the PD parameters representing the maximum drug effect, 149 E_{max} ('true' value = 0.23), and the cipargamin concentration at which half of this 150 effect is achieved, EC_{50} ('true' value = 15.1), have relatively moderate bias with mean 151 posterior median estimates (95% quantiles) of 0.29 (0.23, 0.38) and 17.27 (13.80, 0.29)152 21.12) ng/ml, respectively. These estimates correspond to mean relative biases of 153 26.1% for E_{max} and 14.4% for EC_{50} . These PD parameters, together with γ , define 154 the killing effect of the drug (Equation (2)). As a result, the bias in these estimates 155 produces a noticeable discrepancy in the total number of parasites post-treatment 156 (Figure 4). 157

As with the PK results, we demonstrate that this framework can recover PD 158 model parameters (excluding the mean and spread of the initial parasite age distri-159 bution as described above) for a single experiment by presenting an example of the 160 posterior samples compared to the 'true' value in Figure 5. These show that the 161 true parameter values are well contained within the range of posterior samples for 162 each parameter, considering pairwise correlations. Supplementary Figure S6 shows 163 the posterior predictive PD profiles for each of the eight patients in 3 randomly se-164 lected 8-patient cohorts, again demonstrating that the posterior model fit provides 165 an accurate characterisation of the PD profile. 166

167 **3** Discussion

The results of this simulation-estimation study demonstrate that parameters of the 168 biologically informed PK-PD model can be estimated with relatively high accuracy 169 for Phase 2 volunteer infection studies. The PK parameters in particular were all es-170 timated with very low bias, whereas the estimation of certain PD parameters showed 171 comparatively less precision. In particular, the mean (μ_{ipl}) and standard deviation 172 (σ_{ipl}) of the initial parasite age distribution corresponded to a relative bias of 48.0%173 and 53.3%. However, in absolute terms, this bias corresponds to approximately one 174 hour in the 40-hour parasite life-cycle which does not substantially impact character-175 isation of parasite dynamics. 176

Post-treatment parasite counts are often below the limit of quantification (LOQ). This model accounts for the measurement uncertainty in those data points by averaging across the range [0, LOQ], which provides some information on the relevant parameter values, but less than contributed by points measured above the LOQ. This imperfect observation contributes to the relatively poorer estimation performance of the PD model. Generated datasets that had more post-treatment observations under the LOQ resulted in poorer modelling accuracy (Figure S7).

This form of PK-PD Bayesian hierarchical model has been previously applied to 184 volunteer infection and patient trial datasets [17, 18]. The mechanistic form includes 185 the hourly age of the parasite within the red blood cell for each individual, capturing 186 the asexual reproduction cycle of the parasite and also allowing for the inclusion of the 187 stage specific action of the antimalarial drug. Estimates of the PK-PD model parame-188 ters can be derived using different statistical methods. Maximum likelihood methods 189 are widely used in the analysis of data from early phase antimalarial-drug trials [9, 190 16]. However, these methods are limited, often failing to achieve convergence unless 191

¹⁹² many of the parameter values are fixed. Additionally the methods are restrictive in ¹⁹³ the incorporation of pre-existing data or knowledge. In contrast, Bayesian hierar-¹⁹⁴ chical methods have a number of advantages, such as incorporating prior knowledge ¹⁹⁵ or research, and allowing variation in both the population-level parameter values, ¹⁹⁶ and the correlations between the distributions from which patient-levels values are ¹⁹⁷ drawn.

Pharmaceutical research and development is a costly and time-consuming pro-198 cess [19]. Limited understanding of drug effects can result in the waste of resources 199 though sub-optimal trial design, simultaneously diverting efforts from other candi-200 date treatments. Therefore, careful statistical analysis and interpretation serves to 201 not only maximise the information obtained from a study, but also has the capacity 202 to reduce further inaccuracies; potentially limiting unnecessary risks for patients and 203 minimising delays in antimalarial drug development — and translation into practice. 204 In addition, further computer simulation-estimation studies can be used to determine 205 optimal sampling designs for future Phase 2 and 3 studies (e.g., [20, 21]). 206

Extrapolation and applicability of these simulation results is necessarily limited by the underlying assumptions of the simulation framework. This model is applied with the assumption that the underlying drug and parasite dynamics are identical to the form of the specified model. An area for further investigation would be evaluation of the impact of model misspecification on recovering biological parameters via a simulation-estimation study, whereby PK and/or PD dynamics are simulated under a different model to that used for fitting (e.g., [22]).

The model presented in this paper has been shown to reliably estimate the key population-level PK-PD parameters within the sampling framework from a Phase 2 clinical trial of cipargamin [14], using simulated data. To date, there has been no published formal assessment in a simulation study of the ability of a Bayesian hierarchical PK-PD model to reliably estimate model parameters in the context of malaria. Therefore this paper serves as an example of model performance evaluation through a simulation-estimation approach, and provides confidence in the implementation of similar mechanistic malaria models and inference framework to analyse such data. This flexible model can easily be adapted to study and evaluate emerging antimalarial compounds in the future.

$_{224}$ 4 Methods

Herein we describe the pharmacokinetic (PK) and pharmacodynamic (PD) models,
the simulations generated from each, and the process of estimating model parameters
from simulated data.

228

229 Simulation of cipargamin pharmacokinetic profiles

This study simulated cipargamin concentrations using a standard two-compartment first-order absorption PK model with linear elimination (Text S3 S2), as described in McCarthy *et al.* [14]. The definition of each PK model parameter is given in Table 1. A hierarchical (or mixed-effects) model was used to account for the between- and within-individual variability in cipargamin concentrations.

²³⁵ We simulated 1000 datasets, each with PK profiles for 8 patients, following the ²³⁶ sampling intervals from McCarthy *et al.* [14]. Table 3 contains the population PK ²³⁷ parameters, θ , and between-individual variability, ω , from McCarthy *et al.* [14], and ²³⁸ lower and upper bounds on each PK parameter. The bounds were chosen to allow a ²³⁹ range of feasible values spanning half to double the PK estimates from McCarthy *et* ²⁴⁰ *al.* [14].

Multiplicative error terms for individual observations were drawn from a normal distribution with a mean of 0 with variance σ^2 , and exponentiated. The σ^2 value was generated individually for each dataset, drawn from a log-normal distribution centred at 0.1 (see Text S4 for full details)

245

246 Pharmacodynamic Model

The PD model (presented and developed in [17, 23, 18]) is a mechanistic representation of asexual parasite replication and death during the blood stage of the infection

in the presence of an anti-malarial drug, represented by a series of difference equa-249 tions. Representing parasite age as an integer ranging from 1 to T_{max} , the number 250 of parasites that are a hours old at time t, N(a, t), is given by the number that were 251 a-1 hours old at time t-1. The only unique case is the number that are 1 hour old 252 at t > 0: this is given by the number of parasites that are at the end of the life-cycle 253 (T_{max}) at the previous time step, $N(T_{max}, t-1)$, multiplied by the parasite multi-254 plication factor (PMF), representing the number of new merozoites released into the 255 blood following the asexual reproduction of the parasite at the end of its life cycle. A 256 stage-specific killing effect of cipargamin, E(a,t), at day 7 is then applied to parasites 257 of each age (Equation (1)). Thus, the differences equations governing the parasite 258 distribution are: 259

$$N(a,t) = \begin{cases} N(a-1,t-1) \times (1 - E(a-1,t-1)), & 2 \le a \le T_{max} \\ N(T_{max},t-1) \times (1 - E(T_{max},t-1)) \times PMF, & a = 1. \end{cases}$$
(1)

260

Following inoculation, the initial age-distribution, N(a, 0) is assumed to be normally distributed and discretised into hourly age groups. This distribution is defined by the number of parasites, *ipl*, and the mean, μ_{ipl} , and standard deviation, σ_{ipl} , of the parasite age distribution. During the growth phase, as the parasites age and replicate, the distribution shifts.

The effect of treatment on parasites of age a at time t, E(a, t), is assumed to have Michaelis-Menten kinetics, and depend on the drug concentration (C(t)) the Maximum Killing Effect (E_{max}) , the drug concentration for which 50% of that maximum killing effect is achieved (EC_{50}) , and lastly the sigmoidicity of the concentration-effect 270 curve (γ) :

$$E(a,t) = E_{max} \frac{C(t)^{\gamma}}{C(t)^{\gamma} + EC_{50}^{\gamma}}, \quad E(a,t) \in [0,1].$$
(2)

For this model, the life cycle was set to 40h in order to enable a visual match 271 to the periodic trends of the trial data in McCarthy et al. [14], that were not re-272 producible with a 48h cycle. This is consistent with Wockner *et al.* [24], where it 273 was found that a range of 38.3 to 39.2 hours was the reproductive cycle length most 274 strongly supported by their data from volunteer infection studies. Although Wock-275 ner et al. were using a different parasite dynamic model, these estimates were based 276 on the same strain of malaria and a population of healthy volunteers with no prior 277 malaria infections, similar to the participants of the trial data in McCarthy et al. [14]. 278 279

²⁸⁰ Simulation of parasite density versus time profiles

The 1000 8-patient parasite density-time datasets were simulated using the PD model, 281 each corresponding to one set of simulated PK data. Each profile begins with a 282 growth-phase starting from inoculation, followed by a treatment-phase from day 7 283 onwards. The concentration profiles of the simulated PK data were input into the 284 PD equation to generate the killing effect of the drug during treatment. Individ-285 ual PD parameters were generated via the same approach as described for the PK 286 parameters. That is, patient-level parameters were drawn from population-level dis-287 tributions centred around θ . Drug effect parameters were given by estimates from 288 McCarthy et al. [14], and the parasite multiplication factor informed by [24]. Table 289 5 contains the population PD parameters, θ , and lower and upper bounds on each 290 parameter. Aside from PK input data, the only other factors that varied between 291 simulations were the variance-covariance matrix and noise distribution. 292

293

²⁹⁴ Estimation of pharmacokinetic and pharmacodynamic parameters

For each of the 1000 simulated datasets, parameters were estimated in a Bayesian 295 framework using a Hamiltonian Monte Carlo No U-Turn Sampler in RStan v2.21.0 296 [25] using R version 4.1.1 [26]. For fitting the PK model to the simulated cipargamin 297 concentrations three chains were run with 2000 iterations each and 500 discarded as 298 warm-up. This produced 4500 posterior samples for each PK parameter, from which 299 the posterior median was extracted as a central estimate of the posterior distribu-300 tion. \hat{R} , the effective sample size (n_{eff}) , trace plots and posterior predictive interval 301 plots were assessed to confirm that the chains had converged and were sufficiently 302 will mixed, and that the posterior predictive distributions captured the simulated 303 cipargamin concentration profiles accurately (Figures S2 and S3). 304

For Bayesian modelling of the simulated parasitaemia data, three chains were 305 run with 1000 iterations each and 400 iterations discarded as warm-up, leaving 1800 306 for iterations for analysis. This was fewer than the number of iterations for each 307 PK dataset due to a comparatively longer processing-time to evaluate the likelihood, 308 however visual assessment of the parameter trace plots confirmed adequacy of the 309 burn-in period and suitable convergence. The same diagnostics were evaluated as for 310 the PK model fitting, in order to ensure chains were appropriately well-behaved, and 311 posterior predictive distributions characterised the data (Figure S6). 312

313

314 Graphical Representation

To evaluate the estimation accuracy of the PK-PD model, we compared the posterior medians to the 'true' underlying input values. This comparison of the posteriors medians (mean [95% intervals]) is presented in Tables 4 (for PK parameters) and 6 (PD parameters). Additionally, we plotted the hypothetical profiles that would be produced by each set of posteriors median parameter values. These profiles are presented in Figures 2 and 4 alongside the profile that would be produced by the true population values (i.e. centres of the population parameter distributions).

Figures 3 and 5 present the full distribution of all posterior samples from the STAN fit of a randomly selected single dataset.

All statistical computing code for the simulation and estimation steps is available at https://github.com/M-Tully/pkpd_cipargamin_model.

326 Tables and Figures

Table 1: Definitions of pharmacokinetic model parameters.

Parameter (units)	Definition
Cl (L/h)	Clearance rate of the drug
V_c (L)	Central compartment volume
$Q ({ m L/h})$	Inter-compartmental clearance rate
V_p (L)	Peripheral compartment volume
$k_a (/h)$	Absorption rate

Table 2: Definitions of pharmacodynamic model parameters.

Parameter (units)	Definition
ipl (total #)	Initial Parasite Load. Total number of parasites at inoculation
	or model start
μ_{ipl} (h)	Initial mean parasite age
σ_{ipl} (h)	Standard deviation of the age distribution of the initial parasite
	load
PMF	Parasite multiplication factor. Number of parasites released by
	a ruptured schizont at the end of the life cycle
E_{max} (% killed/h)	Maximal hourly killing rate of the drug
$EC_{50} (ng/mL)$	In vivo drug concentration when killing rate is 50% of E_{max}
γ	Slope of <i>in vivo</i> drug concentration-effect curve

Table 3: Population parameters $(\boldsymbol{\theta})$, and feasible lower (\boldsymbol{b}) and upper (\boldsymbol{a}) bounds for each parameter in the first-order absorption two-compartment pharmacokinetic model for cipargamin.

Parameter (units)	θ	[b,a]
Cl (L/h)	5.5	[2.75, 11]
V_c (L)	64.4	[32.2, 128.8]
Q (L/h)	12.9	[6.45, 25.8]
V_p (L)	107	[53.5, 214]
$k_a (/h)$	0.919	[0.460, 1.838]

Table 4: Mean PK parameter estimates [95% intervals] over 1000 fitted datasets, and associated bias when compared to the values used to simulate the data. Estimates are the posterior median values from a Bayesian hierarchical model.

Parameter	'True'		Bias		
(units)	Value	Posterior Medians	Absolute	Relative $(\%)$	
Cl (L/h)	5.5	$5.41 \ [5.08, \ 5.74]$	$-0.09 \ [-0.42, \ 0.24]$	-1.64 [-7.64, 4.36]	
V_c (L)	64.4	$61.89 \ [46.52, \ 77.84]$	-2.51 [-17.88, 13.44]	-3.90 [-27.76, 20.87]	
Q (L/h)	12.9	12.36 [10.12, 14.40]	-0.54 [-2.78 , 1.50]	-4.19 [-21.55, 11.63]	
V_p (L)	107	$111.44 \ [89.13, \ 139.44]$	$4.44 \left[-17.87, 32.44\right]$	4.15 [-16.70, 30.32]	
$k_a ~(/\mathrm{h})$	0.919	$0.996\ [0.83,\ 1.21]$	$0.08 \ [-0.09, \ 0.29]$	$8.38 \left[-9.68, 31.66\right]$	

Table 5: Population parameters $(\boldsymbol{\theta})$, and feasible lower (\boldsymbol{b}) and upper (\boldsymbol{a}) bounds for each parameter in the pharmacodynamic model.

Parameter (units)	θ	[b,a]
ipl (total #)	1800	[1500, 2100]
μ_{ipl} (h)	2	[1, 24]
σ_{ipl} (h)	3	[1, 14]
PMF	13	[5, 50]
E_{max} (% killed/h)	0.23	[0.05, 1]
$EC_{50} (ng/mL)$	15.1	[0.5, 30]
γ	5	[0.05, 1.838]

Table 6: Mean PD parameter estimates [95% intervals] over 1000 fitted datasets, and associated bias when compared to the values used to simulate the data. Estimates are the posterior median values from a Bayesian hierarchical model.

Parameter	'True'	Bias		
(units)	Value	Posterior Medians	Absolute	Relative $(\%)$
$ipl \ (\# \times 10^3)$	1.8	1.78 [1.75, 1.82]	-0.02 [-0.051, 0.018]	-1.11 [-2.83, 1.00]
μ_{ipl} (h)	2	2.96 [2.69, 3.44]	$0.96 \ [0.69, \ 1.44]$	$48.00 \ [34.50, \ 72.00]$
σ_{ipl} (h)	3	$1.40 \ [1.28, \ 1.55]$	-1.60 [-1.72, -1.45]	-53.33 [-57.33, -48.33]
PMF	13	$14.55 \ [13.48, \ 16.80]$	$1.55 \ [0.48, \ 3.80]$	11.92 [3.69, 29.23]
E_{max} (% killed/h)	0.23	$0.29 \ [0.23, \ 0.38]$	$0.06 \ [0.00, \ 0.15]$	$26.09 \ [0.00, \ 65.22]$
$EC_{50} (ng/mL)$	15.1	17.27 [13.80, 21.12]	2.17 [-1.30, 6.02]	$14.37 \ [-8.61, \ 39.87]$
γ	5	4.72 [2.86, 6.83]	-0.28 [-2.14 , 1.83]	-5.60 [-42.80, 36.60]



Figure 1: Flowchart describing the stages of the current simulation study framework.



Figure 2: PK drug concentration profiles for a 2-compartment model produced from 'true' parameters values used in creating the simulations (black), compared to 1000 profiles created from each of the 1000 dataset's mean estimated values (grey).



Figure 3: Bivariate distributions of posterior samples for population-level PK parameters, from the STAN fit of a single simulated dataset. Red dots indicate 'true' underlying parameter values used to simulate data.



Figure 4: PD parasite profiles produced from 'true' parameters values used to create the simulations (black), compared to 1000 profiles created from each of the 1000 dataset's mean estimated parameter values (grey). Dashed vertical line at day 7 indicates treatment.



Figure 5: Bivariate distributions of posterior samples for population-level PD parameters, from the STAN fit of a single simulated dataset. Red dots indicate 'true' underlying parameter values used to simulate data.

327 **References**

- ³²⁸ [1] World Health Organization; 2023. Geneva: World malaria report 2023. Geneva.
- E. A. Ashley et al. "Spread of artemisinin resistance in Plasmodium falciparum malaria". In: *N Engl J Med* 371.5 (2014), pp. 411–23. ISSN: 1533-4406 (Electronic) 0028-4793 (Print) 0028-4793 (Linking). DOI: 10.1056/NEJMoa1314981.
 URL: https://www.ncbi.nlm.nih.gov/pubmed/25075834.
- B. Balikagala et al. "Evidence of Artemisinin-Resistant Malaria in Africa". In:
 N Engl J Med 385.13 (2021), pp. 1163–1171. ISSN: 1533-4406 (Electronic) 0028 4793 (Linking). DOI: 10.1056/NEJMoa2101746. URL: https://www.ncbi.nlm.
 nih.gov/pubmed/34551228.
- A. Uwimana et al. "Emergence and clonal expansion of in vitro artemisininresistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda".
 In: Nat Med 26.10 (2020), pp. 1602–1608. ISSN: 1078-8956 (Print) 1078-8956.
 DOI: 10.1038/s41591-020-1005-2.
- [5] Luana C. Mathieu et al. "Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in vitro artemisinin resistance". In: *eLife* 9 (2020), e51015. ISSN: 2050-084X. DOI: 10.7554/eLife.51015. URL:
 https://doi.org/10.7554/eLife.51015.
- ³⁴⁵ [6] O. Miotto et al. "Emergence of artemisinin-resistant Plasmodium falciparum
 ³⁴⁶ with kelch13 C580Y mutations on the island of New Guinea". In: *PLoS Pathog*³⁴⁷ 16.12 (2020), e1009133. ISSN: 1553-7366 (Print) 1553-7366. DOI: 10.1371/
 ³⁴⁸ journal.ppat.1009133.
- ³⁴⁹ [7] V. Duru, B. Witkowski, and D. Menard. "Plasmodium falciparum Resistance
 ³⁵⁰ to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria

- Elimination in Cambodia". In: Am J Trop Med Hyg 95.6 (2016), pp. 1228–1238.
 ISSN: 1476-1645 (Electronic) 0002-9637 (Linking). DOI: 10.4269/ajtmh.16 0234. URL: https://www.ncbi.nlm.nih.gov/pubmed/27928074.
- [8] M. Hay et al. "Clinical development success rates for investigational drugs". In:
 Nat Biotechnol 32.1 (2014), pp. 40–51. ISSN: 1546-1696 (Electronic) 1087-0156
 (Linking). DOI: 10.1038/nbt.2786. URL: https://www.ncbi.nlm.nih.gov/
 pubmed/24406927.
- [9] A. N. Abd-Rahman et al. "Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development". In: Antimicrob Agents Chemother 66.2 (2022), e0165921. ISSN: 0066-4804 (Print) 0066-4804. DOI: 10.1128/aac.0165921.
- [10] S. A. Bouwman et al. "The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound". In: *Travel Med Infect Dis* 36 (2020),
 p. 101765. ISSN: 1873-0442 (Electronic) 1477-8939 (Linking). DOI: 10.1016/j.
 tmaid. 2020. 101765. URL: https://www.ncbi.nlm.nih.gov/pubmed/
 32561392.
- [11] E. K. Schmitt et al. "Efficacy of Cipargamin (KAE609) in a Randomized, Phase
 II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated
 Plasmodium falciparum Malaria". In: *Clin Infect Dis* 74.10 (2022), pp. 1831–
 1839. ISSN: 1537-6591 (Electronic) 1058-4838 (Linking). DOI: 10.1093/cid/
 ciab716. URL: https://www.ncbi.nlm.nih.gov/pubmed/34410358.
- G. Ndayisaba et al. "Hepatic safety and tolerability of cipargamin (KAE609),
 in adult patients with Plasmodium falciparum malaria: a randomized, phase
 II, controlled, dose-escalation trial in sub-Saharan Africa". In: *Malar J* 20.1
 (2021), p. 478. ISSN: 1475-2875. DOI: 10.1186/s12936-021-04009-1.

376 [13]	N. J. White et al. "Spiroindolone KAE609 for falciparum and vivax malaria".
377	In: N Engl J Med 371.5 (2014). 1533-4406 White, Nicholas J Pukrittayakamee,
378	Sasithon Phyo, Aung Pyae Rueangweerayut, Ronnatrai Nosten, François Jit-
379	tamala, Podjanee Jeeyapant, Atthanee Jain, Jay Prakash Lefèvre, Gilbert Li,
380	Ruobing Magnusson, Baldur Diagana, Thierry T Leong, F Joel Wellcome Trust/United
381	Kingdom 077166/Wellcome Trust/United Kingdom 093956/Wellcome Trust/United
382	Kingdom 096157/Wellcome Trust/United Kingdom Clinical Trial, Phase II Jour-
383	nal Article Multicenter Study Research Support, Non-U.S. Gov't United States
384	2014/07/31 N Engl J Med. 2014 Jul 31;371(5):403-10. doi: 10.1056/NEJMoa1315860.
385	pp. 403–10. ISSN: 0028-4793 (Print) 0028-4793. doi: 10.1056/NEJMoa1315860.
386 [14]	J. S. McCarthy et al. "Defining the Antimalarial Activity of Cipargamin in
387	Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium fal-
388	ciparum". In: Antimicrobial agents and chemotherapy 65.2 (2021), e01423–20.
389	ISSN: 1098-6596 0066-4804. DOI: 10.1128/AAC.01423-20. URL: https://
390	pubmed.ncbi.nlm.nih.gov/33199389https://www.ncbi.nlm.nih.gov/pmc/
391	articles/PMC7849011/.

³⁹² [15] D. I. Stanisic, J. S. McCarthy, and M. F. Good. "Controlled Human Malaria In³⁹³ fection: Applications, Advances, and Challenges". In: *Infect Immun* 86.1 (2018).
³⁹⁴ ISSN: 1098-5522 (Electronic) 0019-9567 (Print) 0019-9567 (Linking). DOI: 10.
³⁹⁵ 1128 / IAI . 00479 - 17. URL: https://www.ncbi.nlm.nih.gov/pubmed/
³⁹⁶ 28923897.

J. A. Simpson et al. "Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs". In: *Aaps j*16.5 (2014). 1550-7416 Simpson, Julie A Zaloumis, Sophie DeLivera, Alysha M
Price, Ric N McCaw, James M 091625/Wellcome Trust/United Kingdom Jour-

- ⁴⁰¹ nal Article Research Support, Non-U.S. Gov't Review United States 2014/07/25
 ⁴⁰² AAPS J. 2014 Sep;16(5):962-74. doi: 10.1208/s12248-014-9647-y. Epub 2014 Jul
 ⁴⁰³ 24., pp. 962-74. ISSN: 1550-7416. DOI: 10.1208/s12248-014-9647-y.
- [17] S. Dini et al. "Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria". In: *Journal of Antimicrobial Chemotherapy* 76.9 (2021), pp. 2325–2334. ISSN: 0305-7453. DOI:
 10.1093/jac/dkab181. URL: https://doi.org/10.1093/jac/dkab181.
- [18] S. Zaloumis et al. "Assessing the utility of an anti-malarial pharmacokineticpharmacodynamic model for aiding drug clinical development". In: *Malar J*11 (2012), p. 303. ISSN: 1475-2875 (Electronic) 1475-2875 (Linking). DOI: 10.
 1186/1475-2875-11-303. URL: https://www.ncbi.nlm.nih.gov/pubmed/
 22931058.
- [19] K. Smietana, M. Siatkowski, and M. Moller. "Trends in clinical success rates".
 In: Nat Rev Drug Discov 15.6 (2016), pp. 379–80. ISSN: 1474-1784 (Electronic)
 1474-1776 (Linking). DOI: 10.1038/nrd.2016.85. URL: https://www.ncbi.
 nlm.nih.gov/pubmed/27199245.
- ⁴¹⁷ [20] Kris M. Jamsen et al. "Optimal designs for population pharmacokinetic stud⁴¹⁸ ies of the partner drugs co-administered with artemisinin derivatives in pa⁴¹⁹ tients with uncomplicated falciparum malaria". In: *Malaria Journal* 11.1 (2012),
 ⁴²⁰ p. 143.
- ⁴²¹ [21] Jennifer A. Flegg et al. "Optimal sampling designs for estimation of Plasmodium
 ⁴²² falciparum clearance rates in patients treated with artemisinin derivatives". In:
 ⁴²³ Malaria Journal 12.1 (2013), p. 411. DOI: 10.1186/1475-2875-12-411. URL:
 ⁴²⁴ https://doi.org/10.1186/1475-2875-12-411.

29

- [22]David J. Nott, Christopher Drovandi, and David T. Frazier. "Bayesian Infer-425 ence for Misspecified Generative Models". In: Annual Review of Statistics and 426 Its Application (2023). ISSN: 2326-8298. DOI: https://doi.org/10.1146/ 427 annurev-statistics-040522-015915. URL: https://www.annualreviews. 428 org/content/journals/10.1146/annurev-statistics-040522-015915. 429 S. Saralamba et al. "Intrahost modeling of artemisinin resistance in Plasmodium [23]430 falciparum". In: Proceedings of the National Academy of Sciences 108.1 (2010), 431 pp. 397-402. ISSN: 0027-8424 1091-6490. DOI: 10.1073/pnas.1006113108. 432
- [24]L. F. Wockner et al. "Growth Rate of Plasmodium falciparum: Analysis of Par-433 asite Growth Data From Malaria Volunteer Infection Studies". In: J Infect Dis 434 221.6 (2020), pp. 963–972. ISSN: 1537-6613 (Electronic) 0022-1899 (Linking). 435 DOI: 10.1093/infdis/jiz557. URL: https://www.ncbi.nlm.nih.gov/ 436 pubmed/31679015. 437
- Stan Development Team. Stan Modeling Language Users Guide and Reference [25]438 Manual. Version 2.21.0. 2021. URL: https://mc-stan.org. 439
- R Core Team. R: A Language and Environment for Statistical Computing. Ver-[26]440 sion 4.1.1. R Foundation for Statistical Computing. Vienna, Austria, 2021. URL: 441 https://www.R-project.org/.

442

30